As the first CDK4/6i approved by the FDA for use in combination with endocrine therapy in patients with HR+/HER2- advanced breast cancer (ABC), palbociclib demonstrated impressive therapeutic efficacy in the PALOMA-1/TRIO-18 phase II clinical trial. This evidence concerns the gene CDK4 and breast cancer.